You are here: Home » Current Affairs » Coronavirus » News
Business Standard

China Covid-19 vaccine trial halted in Brazil after serious adverse event

Testing of Sinovac Biotech's vaccine, called Coronavac, has been halted in Brazil after an event that occurred on Oct. 29, Brazil Health Agency said without giving any further detail on what happened

China | Coronavirus Vaccine | Coronavirus Tests

Rachel Chang & Simone Iglesias | Bloomberg 

A healthcare worker looks at vaccine
A healthcare worker looks at vaccine

The final-stage trial of a Chinese frontrunner vaccine candidate has been halted in due to a serious adverse event, the first time that any of the Asian nation’s rapidly developed Covid-19 shots have met with such a setback.

Testing of Sinovac Biotech Ltd.’s vaccine, called Coronavac, has been halted in after an event that occurred on Oct. 29, said the Health Agency on Tuesday, without giving any further detail on what happened. The study is interrupted in accordance with regulations while the agency analyses if the study should continue, it said.

Sao Paulo’s Instituto Butantan, which partnered with Sinovac to produce the vaccine locally, said in a statement it was surprised by the decision and is looking into details of what happened in the study. Director Dimas Covas said in a TV interview that one volunteer in the trial has died, but that the death is not related to the vaccine.

Halts to investigate serious adverse events are not uncommon in large-scale drug trials and two western developers - AstraZeneca Plc and Johnson & Johnson -- have paused their vaccine trials in recent months due to such incidents, only to re-start them after investigation.

But has already started administering its vaccines, including Coronavac, to hundreds of thousands of people under an expansive emergency use approval, making the prospect of a safety issue being detected at this stage more concerning.

Sinovac said in a statement on its website that it is confident of the safety of its vaccine. The company said the head of Instituto Butantan reassured it the event that caused the trial’s pause was unrelated to the vaccine.

Defends Giving Experimental Vaccines to Thousands

Last month, China’s science ministry said its companies have inoculated about 60,000 volunteers in final-stage trials, but there have been no reports of serious adverse events.

Serious adverse events that occur in drug trials include death, immediate risk of death, long term or serious incapacitation, and hospitalisation.

The halted test comes after the Sinovac vaccine became the focus of an escalating feud in Brazil. President Jair Bolsonaro stepped up criticism of the vaccine last month, saying lacks credibility to come up with solutions for the crisis and that people wouldn’t feel safe with the shot “due to its origin.”

China’s Foreign Ministry shrugged off the criticism, saying the two countries have “sound cooperation on epidemic control.”

Chinese vaccine developers have been at the forefront of the global race to create an effective immunisation against the virus. The push has taken on vital importance as countries look to move beyond Covid-19 and more definitively re-open their economies. Vaccine development processes that usually take years have been compressed into months by global players, encouraged by politicians wanting a quick fix to the pandemic that has sickened more than 50 million.

The Chinese setback comes as Pfizer Inc. and BioNTech SE released early findings showing that a vaccine they are developing prevented more than 90% of symptomatic infections in the trial of tens of thousands of volunteers, boosting hope for a quick neutralisation of Covid-19.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, November 10 2020. 13:05 IST